TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15288082

Group type: EXPERIMENTAL
Intervention: Non nutritive pacifier sucking (T)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Local application of Emla with non nutritive pacifier sucking (E)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral administration of 30% saccharose solution with non nutritive pacifier sucking (S)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral administration of 30% saccharose solution with local application of Emla and with non nutritive pacifier sucking (S + E)
Number of subjects: 33
Study: 11323125

Group type: EXPERIMENTAL
Intervention: Pain beliefs
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Catastrophizing
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Beliefs
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Objective measure of jaw impairment
Number of subjects: 118
Study: 9596385

Group type: EXPERIMENTAL
Intervention: Combined exercise and motivation program
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard exercise program
Number of subjects: 93
Study: 8164926

Group type: EXPERIMENTAL
Intervention: Continuous combined regimen with 2.5 mg of MPA (Group A)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Continuous combined regimen with 5.0 mg of MPA (Group B)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Sequential regimen with 5.0 mg of MPA (Group C)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Sequential regimen with 10.0 mg of MPA (Group D)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens alone (Group E)
Number of subjects: 1724
Study: 2904752

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 228

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 228
Study: 30833373

Group type: EXPERIMENTAL
Intervention: BDI score <10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDI score ≥10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDI score ≥10 and ADM use
Number of subjects: 0

Group type: COMPARATOR
Intervention: No ADM use
Number of subjects: 0
Study: 26293750

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Higher levels of depressive symptoms
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fewer drug-related problems
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: No use of hard drugs within the prior 30 days
Number of subjects: 79
Study: 25601341

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 1088
Study: 23835495

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO₃)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl)
Number of subjects: 120
Study: 20233897

Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation for 20 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (compressed air) for 20 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 7.5% CO2 inhalation on day 2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (compressed air) on day 2
Number of subjects: 12
Study: 19485973

Group type: EXPERIMENTAL
Intervention: Baseline glucose levels
Number of subjects: 1324
Study: 16820555

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (1 to 3 mg/h for 48 hours)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oral metoprolol (25 mg twice per day to 50 mg 3 times per day starting on the first postoperative morning)
Number of subjects: 240
Study: 14509562

Group type: EXPERIMENTAL
Intervention: Formoterol 54 microg via Turbuhaler
Number of subjects: 88

Group type: COMPARATOR
Intervention: Salbutamol 2400 microg via pMDI plus spacer
Number of subjects: 88
Study: 10849056

Group type: EXPERIMENTAL
Intervention: 14 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 7 days of lansoprazole (30 mg once daily), clarithromycin (250 mg twice daily), and amoxicillin (500 mg three times daily)
Number of subjects: 46
Study: 9061892

Group type: EXPERIMENTAL
Intervention: Accountability manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study: 8400591

Group type: EXPERIMENTAL
Intervention: Diet A (100% soybean oil)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diet B (50:50 mixture of soybean oil and medium-chain triglycerides)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diet C (42.5% MCT, 50% soybean oil, and 7.5% blackcurrant seed oils)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 36

Group type: COMPARATOR
Intervention: All diets
Number of subjects: 36
Study: 2948143

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zomepirac 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30430515

Group type: EXPERIMENTAL
Intervention: Group training in the mental image
Number of subjects: 37

Group type: COMPARATOR
Intervention: Group 2 of reference
Number of subjects: 37
Study: 27365164

Group type: EXPERIMENTAL
Intervention: Capillary drug concentrations after administration of a single dose of antipsychotic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venous drug concentrations after administration of a single dose of antipsychotic drugs
Number of subjects: 0
Study: 24587878

Group type: EXPERIMENTAL
Intervention: HyFence LV
Number of subjects: 74

Group type: COMPARATOR
Intervention: Guardix-Sol (HA-CMC)
Number of subjects: 74
Study: 22963750

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G-CSF/CPC
Number of subjects: 32
Study: 20547424

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 40
Study: 18476965

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 100 mg (group III)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral sildenafil 25 mg (group II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral sildenafil 100 mg (group V)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with PGE1 (5 microg) and oral placebo (group IV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection (ICI) with trimix (0.25 mL) and oral placebo (group I)
Number of subjects: 80
Study: 16161380

Group type: EXPERIMENTAL
Intervention: Airflow-cooling blanket
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waterflow-cooling blanket
Number of subjects: 0
Study: 12647260

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 40
Study: 10867332

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Simvastatin 20 mg daily
Number of subjects: 87
Study: 8892095

Group type: EXPERIMENTAL
Intervention: In vitro culture in T‐cell growth factor/interleukin 2 and 4-containing medium (TCGF/IL2/IL4)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Peripheral blood mononuclear cells (PBMC) expanded in TCGF/IL2/IL4
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Freshly obtained CSF cells stimulated directly with myelin basic protein (MBP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mitogen stimulation of expanded CSF cells
Number of subjects: 21
Study: 8213302

Group type: EXPERIMENTAL
Intervention: Inpatient detoxification
Number of subjects: 43
Study: 3476982

Group type: EXPERIMENTAL
Intervention: Experimental replantation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 29161349

Group type: EXPERIMENTAL
Intervention: Retinal (macular pigment optical density/MPOD) and blood serum concentrations of lutein and zeaxanthin in older adults
Number of subjects: 54

Group type: COMPARATOR
Intervention: Younger adults (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin (L&Z)
Number of subjects: 54
Study: 27312107

Group type: EXPERIMENTAL
Intervention: Longer duration of neutropenia (measured in days)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Number of sterile site infections
Number of subjects: 569
Study: 26450249

Group type: EXPERIMENTAL
Intervention: Care home residents
Number of subjects: 708
Study: 23092173

Group type: EXPERIMENTAL
Intervention: Psoriasis Symptom Inventory (PSI)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Dermatology Life Quality Index (DLQI)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: SF-36v2 Acute
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Patient Global Assessment (PtGA)
Number of subjects: 143
Study: 21134844

Group type: EXPERIMENTAL
Intervention: 30‐s TV ad simulation
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: billboard simulation
Number of subjects: 279

Group type: COMPARATOR
Intervention: no‐information condition
Number of subjects: 279
Study: 18184251

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 17313848

Group type: EXPERIMENTAL
Intervention: Dual therapy (tacrolimus + glucocorticoid)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Triple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (tacrolimus + mycophenolate mofetil + glucocorticoid + daclizumab)
Number of subjects: 94
Study: 12638645

Group type: EXPERIMENTAL
Intervention: Treatment for tobacco dependence in alcoholic smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic options for tobacco dependence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral therapy and 12-step approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Further research on effective treatments
Number of subjects: 0
Study: 10798820

Group type: EXPERIMENTAL
Intervention: Lamotrigine (25 mg once daily for 1 week, 50 mg once daily for the second week, and 100 mg once daily for the last 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lithium (400 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 7625346

Group type: EXPERIMENTAL
Intervention: Folic acid supplement (SL; 300 micrograms/d, n = 14)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo lactating (PL; n = 15)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo formula feeding (FF; n = 18)
Number of subjects: 71
Study: 2522902

Group type: EXPERIMENTAL
Intervention: Short-acting GnRH agonist (100-500 micrograms daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Long-acting GnRH agonist (3.2 mg intramuscularly)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Combined GnRH-agonist/gonadotropin stimulation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 119
Study: 331057

Group type: EXPERIMENTAL
Intervention: Kavain (200 mg per capsule, 2 capsules per day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (2 capsules per day)
Number of subjects: 84
Study: 31787759

Group type: EXPERIMENTAL
Intervention: One-layer vasovasostomy with stent (n = 23)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Two-layer vasovasostomy (n = 19)
Number of subjects: 42
Study: 31023363

Group type: EXPERIMENTAL
Intervention: Nasal high-frequency oscillatory ventilation (nHFOV) started immediately after extubation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 6
Study: 28296618

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide
Number of subjects: 562

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide (MGMT methylated)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Radiotherapy alone (MGMT methylated)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide (MGMT unmethylated)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Radiotherapy alone (MGMT unmethylated)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 562
Study: 25892513

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca[OH]2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca[OH]2) + chlorhexidine (CHX)
Number of subjects: 20
Study: 23349082

Group type: EXPERIMENTAL
Intervention: IF‐‐SRS completed in presence of therapist and results discussed immediately afterward
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Next Session Feedback‐‐SRS completed alone and results discussed next session
Number of subjects: 102

Group type: COMPARATOR
Intervention: No Feedback‐‐SRS completed alone and results not available to therapist
Number of subjects: 102
Study: 20197485

Group type: EXPERIMENTAL
Intervention: CS-8958 (20 mg inhaled dose)
Number of subjects: 20
Study: 19811351

Group type: EXPERIMENTAL
Intervention: 100 mg LOS + 25 mg HCTZ (test formulation)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference formulation (Hyzaar)
Number of subjects: 28
Study: 16762012

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide (TA) injection (0.5 ml at 40 mg/ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 45
Study: 14770445

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa fixed dose (325 microg)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa weight-based dose (4.5 microg/kg)
Number of subjects: 242
Study: 11423594

Group type: EXPERIMENTAL
Intervention: Active TENS plus standard medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medication only (midazolam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non‐functioning TENS and standard medication
Number of subjects: 0
Study: 9233202

Group type: EXPERIMENTAL
Intervention: Experimental group (received at least one breastfeeding education class)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no breastfeeding education class)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Multiparous women (previously bottle-fed children)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Primiparous women
Number of subjects: 31
Study: 7827883

Group type: EXPERIMENTAL
Intervention: Polydioxanone suture
Number of subjects: 813

Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 813
Study: 2464223

Group type: EXPERIMENTAL
Intervention: BOMP (bleomycin, vincristine, mitomycin and cisplatin)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CEP (cyclophosphamide, 4'-epidoxorubicin and procarbazine)
Number of subjects: 38
Study: 30178886

Group type: EXPERIMENTAL
Intervention: Dairy diet
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nondairy diet
Number of subjects: 108
Study: 26559713

Group type: EXPERIMENTAL
Intervention: Why-to-quit advertisements (graphic imagery and personal testimonial)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Cessation cognitions (positive)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Nicotine dependence level
Number of subjects: 354
Study: 25494967

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 2000 or 500 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone (ivMP) 7.5 g
Number of subjects: 32
Study: 24289512

Group type: EXPERIMENTAL
Intervention: Protocolised care (two experimental approaches)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual 'wild type' care
Number of subjects: 0
Study: 22018131

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Contraceptive vaginal rings (daily release of 15 mcg ethinyl estradiol/120 mcg etonogestrel)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills
Number of subjects: 33

Group type: COMPARATOR
Intervention: Contraceptive vaginal rings
Number of subjects: 33
Study: 18430854

Group type: EXPERIMENTAL
Intervention: MR angiography (MRA)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: CT angiography (CTA)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Duplex sonography
Number of subjects: 514

Group type: COMPARATOR
Intervention: MRA
Number of subjects: 514
Study: 16489935

Group type: EXPERIMENTAL
Intervention: Serial sweeping of the membranes (every 48 hours until labour commenced up to 42 weeks of gestation)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Serial sweeping of the membranes (for nulliparous women)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Serial sweeping of the membranes (for parous women)
Number of subjects: 742

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 742
Study: 12837902

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10787361

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg (n = 1380)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Lower‐extremity fractures
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Inpatient surgery
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Nonsurgical hospitalization
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 2763
Study: 8831313

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (ITS)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Epidural bupivacaine (EB)
Number of subjects: 129
Study: 1485178

Group type: EXPERIMENTAL
Intervention: Ondansetron 1 mg, 4 mg, or 8 mg, three times per day for 3 days
Number of subjects: 673

Group type: COMPARATOR
Intervention: Ondansetron (all doses)
Number of subjects: 673
Study: 6729868

Group type: EXPERIMENTAL
Intervention: Pendulum therapy (2000 cGy in ten fractions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stationary field therapy (2000 cGy in ten fractions)
Number of subjects: 0
Study: 31274828

Group type: EXPERIMENTAL
Intervention: CETSOL VR Clinic software
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional simulated role-play in a real clinical environment
Number of subjects: 76
Study: 30367673

Group type: EXPERIMENTAL
Intervention: Sucrose vaginal gel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Metronidazole vaginal gel
Number of subjects: 70
Study: 24346164

Group type: EXPERIMENTAL
Intervention: Multilevel models with varying individual-level variances and correlations across treatment arms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multilevel models with fixed individual-level variances and correlations across treatment arms
Number of subjects: 0
Study: 24726342

Group type: EXPERIMENTAL
Intervention: 300μg indacaterol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21894688

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to Guanyuan (CV 4), Zhongji (CV 3), Sanyinjiao (SP 6), Zigong (EX‐CA 1), and Taixi (KI 3) in the observation group.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) in the observation group.
Number of subjects: 66
Study: 18435426

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery plus medical therapy
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 1066
Study: 16406997

Group type: EXPERIMENTAL
Intervention: 0.3 M potassium chloride (KCl)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 17
Study: 15353496

Group type: EXPERIMENTAL
Intervention: Preoperative delayed-enhancement MRI
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Preoperative dysfunctional segments
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transmural extent of hyperenhancement
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Previously dysfunctional but nonenhancing or minimally hyperenhancing segments
Number of subjects: 52
Study: 11419683

Group type: EXPERIMENTAL
Intervention: Mebendazole 200 mg thrice daily for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole 15 mg/kg/day in three divided doses for 7 days
Number of subjects: 100
Study: 9268175

Group type: EXPERIMENTAL
Intervention: Dalteparin (low molecular weight heparin), given subcutaneously once daily
Number of subjects: 164

Group type: COMPARATOR
Intervention: Unfractionated heparin, continuous intravenous infusion
Number of subjects: 164
Study: 8111817

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 30 mg/day
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 60 mg/day
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core 90 mg/day
Number of subjects: 251

Group type: COMPARATOR
Intervention: ATN + placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core (all doses)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Nifedipine coat-core
Number of subjects: 251
Study: 3103730

Group type: EXPERIMENTAL
Intervention: 30 mg aminohydroxypropylidene diphosphonate
Number of subjects: 16
Study: 934677

Group type: EXPERIMENTAL
Intervention: New variants of the Pinkel treatment scheme
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study: 31241356

Group type: EXPERIMENTAL
Intervention: Emotional Intelligence training (EmotivaMente)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study: 28421294

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with intravesical chemotherapy (group A)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (group B)
Number of subjects: 283
Study: 27259298

Group type: EXPERIMENTAL
Intervention: Hypoglycemic and antihypertensive drug use
Number of subjects: 923